Pfizer (PFE) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Pfizer Inc. (PFE) insider buying and selling: 3 purchases, 2 sales
26 Form 4 Table I transactions filed with the SEC by Pfizer Inc. insiders between 2026-02-02 and 2026-08-12 (15-month history): 3 open-market purchases and 2 sales, plus 21 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a purchase of $1.0M by Bourla Albert on 2026-08-12.
Pfizer insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Pfizer insiders filed 3 purchases worth $3.0M and 2 sales worth $135k on the open market. The net balance is on the buy side: $2.8M more bought than sold.
The biggest buyer was Bourla Albert (Chairman & CEO): $1.0M in 1 purchase, out of 3 different buyers. The biggest seller was Damico Jennifer B. (SVP & Controller): $135k in 2 sales, the only seller.
The largest trade of the period was a purchase of $1.0M on Aug 12, 2026, by Bourla Albert (Chairman & CEO). Form 4 on sec.gov (0001225208-26-007083).
None of the 2 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 3 purchases and 1 sale, against 0 and 1 in the three before. The latest purchase is from Aug 12, 2026; the latest sale from Aug 5, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Pfizer has more sales than 8 of the other 58, ranks 3 of 59 by net dollars bought, and 19 of the 59 have at least one purchase, Pfizer included.
The 20 most important trades
The 3 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 26 PFE trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-12 | 2026-08-12 | Bourla Albert | Chairman & CEO | $1.0M | P — Open-market purchase | SEC |
| 2026-08-05 | 2026-08-05 | Blaylock Ronald E | Director | $999k | P — Open-market purchase | SEC |
| 2026-08-05 | 2026-08-05 | Buckley Mortimer J | Director | $960k | P — Open-market purchase | SEC |
| 2026-08-05 | 2026-08-06 | Damico Jennifer B. | SVP & Controller | $83k | S — Open-market sale | SEC |
| 2026-06-09 | 2026-06-10 | Damico Jennifer B. | SVP & Controller | $51k | S — Open-market sale | SEC |
| 2026-02-25 | 2026-02-27 | Bourla Albert | Chairman & CEO | $16.6M | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Bourla Albert | Chairman & CEO | $12.8M | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-02-25 | 2026-02-27 | Lankler Douglas M | Executive Vice President | $4.2M | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Lankler Douglas M | Executive Vice President | $3.2M | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-02-25 | 2026-02-27 | Fonseca Lidia | Executive Vice President | $1.9M | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Sahni Payal | Executive Vice President | $1.9M | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Sahni Payal | Executive Vice President | $1.5M | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-02-25 | 2026-02-27 | Fonseca Lidia | Executive Vice President | $1.5M | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-02-25 | 2026-02-27 | Mcdermott Michael | Executive Vice President | $1.3M | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Mcdermott Michael | Executive Vice President | $989k | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-02-25 | 2026-02-27 | Damico Jennifer B. | SVP & Controller | $594k | M — Option exerciseForm 4 footnoteF1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Damico Jennifer B. | SVP & Controller | $459k | F — Tax withholding (shares surrendered for taxes)3 Form 4 footnotesF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. | SEC |
| 2026-01-30 | 2026-02-02 | Boshoff Christoffel | President, R&D | $341k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). | SEC |
| 2026-02-25 | 2026-02-27 | Boshoff Christoffel | President, R&D | $185k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon). | SEC |
| 2026-02-26 | 2026-02-27 | Mcdermott Michael | Executive Vice President | $95k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF5 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Feb 2, 2026 and Aug 12, 2026, Pfizer Inc. open-market activity adds up to 3 purchases worth $3.0M and 2 sales worth $135k. The net balance is $2.8M on the buy side.
Only codes P and S count, where an insider puts in or takes out their own money. A buying balance like Pfizer Inc.'s is the less common case in the S&P 500: its insiders are already paid in stock and still put in their own money. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 13 | $21.1M |
| M | Option exercise | 6 | $26.5M |
| P | Open-market purchase | 3 | $3.0M |
| A | Grant or award | 2 | $0 |
| S | Open-market sale | 2 | $135k |
| Total | Everything filed in the period | 26 | $50.7M |
2 of the 26 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 9 distinct people or entities have filed Pfizer Inc. transactions: 3 bought on the open market and 1 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Bourla Albert | Chairman & CEO | 3 | $1.0M (1) | — | 2026-08-12 |
| Blaylock Ronald E | Director | 1 | $999k (1) | — | 2026-08-05 |
| Buckley Mortimer J | Director | 1 | $960k (1) | — | 2026-08-05 |
| Damico Jennifer B. | SVP & Controller | 8 | — | $135k (2) | 2026-08-06 |
| Boshoff Christoffel | President, R&D | 4 | — | — | 2026-02-27 |
| Mcdermott Michael | Executive Vice President | 3 | — | — | 2026-02-27 |
| Fonseca Lidia | Executive Vice President | 2 | — | — | 2026-02-27 |
| Lankler Douglas M | Executive Vice President | 2 | — | — | 2026-02-27 |
Shown here are the 8 who moved the most money, out of 9. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 3 purchases and 1 sale, worth $3.0M. 13 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 1 | $51k |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 3 | $3.0M | 1 | $83k |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Pfizer Inc. (PFE) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 2 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Pfizer's 3 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Aug 12, 2026, and a Form 4 arrives up to two business days after the trade.
15 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.